Literature DB >> 3191073

How do general practitioners manage eye disease in the community?

P J McDonnell1.   

Abstract

A survey of the management of eye disease in the community was carried out in two general practices over a three-month period. During this time there were 238 consultations by patients with ocular symptoms, making up 2.3% of all consultations and giving an annual consultation rate for eye disease of 66 per 1000 persons at risk. The four commonest diagnoses were bacterial conjunctivitis, allergic conjunctivitis, meibomian cyst, and blepharitis, and these accounted for more than 70% of the consultations. A variety of topical and systemic treatments were used, with topical chloramphenicol prescribed in 55% of consultations. Referral to a hospital eye department resulted from 35 consultations, giving a referral rate of 15% of all consultations.

Entities:  

Mesh:

Year:  1988        PMID: 3191073      PMCID: PMC1041572          DOI: 10.1136/bjo.72.10.733

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  4 in total

1.  Eye disease at a community health centre.

Authors:  J K Dart
Journal:  Br Med J (Clin Res Ed)       Date:  1986-12-06

2.  Use of steroid eye drops in general practice.

Authors:  M J Lavin; G E Rose
Journal:  Br Med J (Clin Res Ed)       Date:  1986-05-31

3.  Steroids, the eye, and general practitioners.

Authors:  D St Clair Roberts
Journal:  Br Med J (Clin Res Ed)       Date:  1986-05-31

4.  The red eye: a general practice survey.

Authors:  A Wilson
Journal:  J R Coll Gen Pract       Date:  1987-02
  4 in total
  27 in total

Review 1.  Topical antibiotics for acute bacterial conjunctivitis: a systematic review.

Authors:  A Sheikh; B Hurwitz
Journal:  Br J Gen Pract       Date:  2001-06       Impact factor: 5.386

2.  Shifting trends in in vitro antibiotic susceptibilities for common bacterial conjunctival isolates in the last decade at the New York Eye and Ear Infirmary.

Authors:  Adebukola Adebayo; Jignesh G Parikh; Steven A McCormick; Mahendra K Shah; Remedios S Huerto; Guopei Yu; Tatyana Milman
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-06-08       Impact factor: 3.117

Review 3.  Primary care and ophthalmology in the United Kingdom.

Authors:  S F Riad; J K G Dart; R J Cooling
Journal:  Br J Ophthalmol       Date:  2003-04       Impact factor: 4.638

4.  General practitioners' confidence in diagnosing and managing eye conditions: a survey in south Devon.

Authors:  P I Featherstone; C James; M S Hall; A Williams
Journal:  Br J Gen Pract       Date:  1992-01       Impact factor: 5.386

5.  The treatment of acute infectious conjunctivitis with fusidic acid: a randomised controlled trial.

Authors:  Remco P Rietveld; Gerben ter Riet; Patrick J E Bindels; Dick Bink; Jacobus H Sloos; Henk C P M van Weert
Journal:  Br J Gen Pract       Date:  2005-12       Impact factor: 5.386

6.  Evaluation of eLearning for the teaching of undergraduate ophthalmology at medical school: a randomised controlled crossover study.

Authors:  Caroline A Petrarca; Julia Warner; Andrew Simpson; Robert Petrarca; Abdel Douiri; David Byrne; Timothy L Jackson
Journal:  Eye (Lond)       Date:  2018-05-25       Impact factor: 3.775

7.  A prospective study of cost, patient satisfaction, and outcome of treatment of chalazion by medical and nursing staff.

Authors:  T L Jackson; L Beun
Journal:  Br J Ophthalmol       Date:  2000-07       Impact factor: 4.638

8.  Toxic epidermal necrolysis: the red eye and red herrings in casualty.

Authors:  Robert J Barry; Ulises Zanetto; Sai Kolli; Rupal Morjaria
Journal:  BMJ Case Rep       Date:  2018-10-12

9.  Management of ophthalmic disease in general practice.

Authors:  J H Sheldrick; A D Wilson; S A Vernon; C M Sheldrick
Journal:  Br J Gen Pract       Date:  1993-11       Impact factor: 5.386

10.  Effectiveness, tolerability and safety of azithromycin 1% in DuraSite for acute bacterial conjunctivitis.

Authors:  Susannah McLean; Aziz Sheikh
Journal:  Patient Prefer Adherence       Date:  2010-05-13       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.